REMARKS/ARGUMENTS

Claims 11-12, 17-25 and 43-65 are now pending. Claims 11, 18, and 22-24 are currently amended, and claims 1-10, 13-16 and 25-42 have been cancelled, without prejudice or disclaimer of any previously claimed subject matter. Claims 43-65 are new. Applicants reserve the right to pursue the previously claimed subject matter in one or more continuation or divisional applications.

In the Office Action dated January 11, 2006, the Examiner imposed a restriction requirement, and restricted the prosecution of the application to one of forty groups:

- I. Claims 1, 26-32, and 37-42, drawn to compounds and of claim 1.
- II. Claims 2, 26-32, and 37-42, drawn to compounds of claim 2.
- III. Claims 3, 26-32, and 37-42, drawn to compounds of claim 3.
- IV. Claims 4, 26-32, and 37-42, drawn to compounds of claim 4.
- V. Claims 5, 26-32, and 37-42, drawn to compounds of claim 5.
- VI. Claims 6, 26-32, and 37-42, drawn to compounds of claim 6.
- VII. Claims 7, 26-32, and 37-42, drawn to compounds of claim 7.
- VIII. Claims 8, 26-32, and 37-42, drawn to compounds of claim 8.
- IX. Claims 9-11, 26-32, and 37-42, drawn to compounds of claim 9.
- X. Claims 10, 26-32, and 37-42, drawn to compounds of claim 10.

XI-XX. Claims 11-12, 17-25, drawn to methods of treating a host infected with a *Flaviviridae* infection by administering a compound from groups I-IX.

XXI-XXX. Claims 13-16, drawn to methods of treating a host infected with a *Flaviviridae* infection by administering a compound from groups I-IX and an additional antiviral agent.

XXXI-XXXX. Claims 33-36, drawn to compositions comprising the compounds of group I-IX and an additional antiviral agent.

Applicants elect Group XV (claims 11-12, and 17-25) drawn to methods of treating a host infected with a *Flaviviridae* infection by administering a compound of formula V as recited in claim 5. Claims 11-12, 17-25 and new claims 43-65 read on the elected Group.

Appl. No. 10/609,298 Amendment dated May 11, 2006 Reply to Office Action of January 11, 2006

The Examiner has also requested that Applicant elect a disclosed species for prosecution under 35 U.S.C. § 121. Applicants elect the compound recited in amended claim 11, wherein R¹ is H, R² is an ester of an amino acid, X¹ is H and Y is NH₂. Claims 11-25, and new claims 43, 46, 48, 53-55, and 62-65 read on the elected species.

Claim 11 has been amended to reflect the elected Group. Claims 1-10 and 26-42 which do not read on the elected Group have been cancelled.

Examination of the amended claims is respectfully requested. The Commissioner is authorized to charge any deficiency to Deposit Account 11-0980.

Respectfully submitted,

Reg. No. 33,052

Date: May 11, 2006

KING & SPALDING LLP 1180 Peachtree Street 34th Floor Atlanta, Georgia 30309